SCHEMBL13028569

SCHEMBL13028569

O=S(=O)(Nc1cccc(CCO)c1)c1ccc(Br)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.63
HTR6 P50406 6/20 0.57
ITGA1 P56199 1/20 0.56
IKBKB O14920 1/20 0.55
CYP19A1 P11511 2/20 0.51
PHGDH O43175 1/20 0.51
MAPT P10636 2/20 0.49
AR P10275 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
EGFR P00533 1/20 0.48
ERBB2 P04626 1/20 0.48
MCL1 Q07820 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2894635 0.96 HSD17B2 (0.59) HSD17B2HTR6ITGA1IKBKBCYP19A1
SCHEMBL2889176 0.89 IKBKB (0.69) HSD17B2HTR6ITGA1IKBKBCYP19A1
SCHEMBL13028493 0.85 IKBKB (0.64) HSD17B2HTR6ITGA1IKBKBCYP19A1
SCHEMBL15232982 0.80 UCHL1 (0.58) HSD17B2HTR6ITGA1IKBKBCYP19A1
SCHEMBL2236047 0.80 HTR6 (0.59) HSD17B2HTR6ITGA1IKBKBCYP19A1
SCHEMBL13028496 0.79 UCHL1 (0.57) HTR6MAPTARSMN1; SMN2CYP1A2
SCHEMBL2896014 0.78 CYP19A1 (0.56) HTR6IKBKBCYP19A1PHGDHMAPT
SCHEMBL1712411 0.78 HTR6 (0.51) HTR6IKBKBPHGDHMAPTMCL1
SCHEMBL10513396 0.77 PTPN1 (0.62) HTR6IKBKBPHGDH
SCHEMBL2894674 0.76 NHERF1 (0.57) HSD17B2ITGA1IKBKBMAPTAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137141-B1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS UNIV ABERDEEN (GB) 2015-12-02 EP disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents ARSA, SOST, AHR HSD17B2 3104/4885HTR6 1885/4885ITGA1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.